KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) EBT Margin (2016 - 2025)

Charles River Laboratories International has reported EBT Margin over the past 17 years, most recently at 29.58% for Q4 2025.

  • Quarterly results put EBT Margin at 29.58% for Q4 2025, down 796.0% from a year ago — trailing twelve months through Dec 2025 was 2.48% (down 478.0% YoY), and the annual figure for FY2025 was 2.48%, down 478.0%.
  • EBT Margin for Q4 2025 was 29.58% at Charles River Laboratories International, down from 8.68% in the prior quarter.
  • Over the last five years, EBT Margin for CRL hit a ceiling of 22.27% in Q4 2022 and a floor of 29.58% in Q4 2025.
  • Median EBT Margin over the past 5 years was 11.89% (2022), compared with a mean of 8.52%.
  • Biggest five-year swings in EBT Margin: soared 419bps in 2022 and later tumbled -4222bps in 2024.
  • Charles River Laboratories International's EBT Margin stood at 18.08% in 2021, then increased by 23bps to 22.27% in 2022, then fell by -8bps to 20.59% in 2023, then crashed by -205bps to 21.62% in 2024, then tumbled by -37bps to 29.58% in 2025.
  • The last three reported values for EBT Margin were 29.58% (Q4 2025), 8.68% (Q3 2025), and 6.92% (Q2 2025) per Business Quant data.